YD Bio Statistics
Total Valuation
YD Bio has a market cap or net worth of $977.80 million. The enterprise value is $974.69 million.
Important Dates
The last earnings date was Tuesday, September 30, 2025, after market close.
| Earnings Date | Sep 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
YD Bio has 70.32 million shares outstanding. The number of shares has increased by 4.01% in one year.
| Current Share Class | 70.32M |
| Shares Outstanding | 70.32M |
| Shares Change (YoY) | +4.01% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 0.25% |
| Float | 69.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.81 |
| Forward PS | n/a |
| PB Ratio | 3.04 |
| P/TBV Ratio | 250.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,909.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.18, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.18 |
| Quick Ratio | 12.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,893.69 |
Financial Efficiency
Return on equity (ROE) is -42.69% and return on invested capital (ROIC) is -27.34%.
| Return on Equity (ROE) | -42.69% |
| Return on Assets (ROA) | -25.43% |
| Return on Invested Capital (ROIC) | -27.34% |
| Return on Capital Employed (ROCE) | -22.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | 6.65 |
Taxes
In the past 12 months, YD Bio has paid $25,080 in taxes.
| Income Tax | 25,080 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.23% in the last 52 weeks. The beta is 0.12, so YD Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +21.23% |
| 50-Day Moving Average | 14.09 |
| 200-Day Moving Average | 12.62 |
| Relative Strength Index (RSI) | 60.02 |
| Average Volume (20 Days) | 93,472 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, YD Bio had revenue of $510,360 and -$1.41 million in losses. Loss per share was -$1.29.
| Revenue | 510,360 |
| Gross Profit | 155,356 |
| Operating Income | -1.46M |
| Pretax Income | -1.39M |
| Net Income | -1.41M |
| EBITDA | -1.36M |
| EBIT | -1.46M |
| Loss Per Share | -$1.29 |
Full Income StatementBalance Sheet
The company has $3.13 million in cash and $22,265 in debt, giving a net cash position of $3.11 million or $0.04 per share.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | 22,265 |
| Net Cash | 3.11M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 6.59M |
| Book Value Per Share | 4.57 |
| Working Capital | 3.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.84 million and capital expenditures -$74,914, giving a free cash flow of -$1.91 million.
| Operating Cash Flow | -1.84M |
| Capital Expenditures | -74,914 |
| Free Cash Flow | -1.91M |
| FCF Per Share | -$0.03 |
Full Cash Flow StatementMargins
Gross margin is 30.44%, with operating and profit margins of -286.45% and -276.58%.
| Gross Margin | 30.44% |
| Operating Margin | -286.45% |
| Pretax Margin | -271.67% |
| Profit Margin | -276.58% |
| EBITDA Margin | -265.93% |
| EBIT Margin | -286.45% |
| FCF Margin | n/a |